We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Adaptable Lateral Flow Test Reader Being Promoted at AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2016
Print article
Image: The ADxLR5 lateral flow assay reader (Photo courtesy of Abingdon Health).
Image: The ADxLR5 lateral flow assay reader (Photo courtesy of Abingdon Health).
A lateral flow test reader for either existing assays or for user-designed tests will be highlighted at the 2016 AACC Annual Meeting & Clinical Lab Expo (Philadelphia, PA, USA).

Abingdon Health (York, United Kingdom) will be highlighting its [U.S.] Food and Drug Administration registered and CE marked lateral flow reader, the ADxLR5, in Booth 3838 at the Philadelphia meeting.

The next generation ADxLR5 Lateral Flow Assay reader incorporates a 10.1-inch touch screen with graphical user interface and icon driven software. The sample draw with interchangeable inserts allows for the reading of a wide range of devices and assays. Connectivity is via two USB ports, Ethernet connection, or WiFi.

The ADxLR5 reader complements Abingdon Health's Seralite – FLC (free light chain) rapid test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories with results available in about 10 minutes rather than days or weeks.

In addition, The ADxLR5 is fully customizable for user-designed fluorescence or colorimetric tests and is compatible with most formats of cassettes and test strips. The instrument includes touchscreen PC software to augment flexible test system development.

Related Links:
AACC Annual Meeting & Clinical Lab Expo
Abingdon Health
Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.